Vericel Corporation $VCEL Shares Acquired by CenterBook Partners LP
CenterBook Partners LP significantly increased its stake in Vericel Corporation (NASDAQ:VCEL) by 171.1% in the third quarter, now owning 184,986 shares valued at approximately $5.82 million. Other institutional investors have also adjusted their holdings. Analysts have a "Moderate Buy" consensus rating for VCEL, with a target price of $57.50, against its recent trading price near $36.82.
Vericel stock hits 52-week high at $35.84 despite yearly decline By Investing.com
Vericel Corporation's stock (VCEL) recently hit $35.84, a high despite a 38% decline over the past year. Analysts maintain a "strong buy" consensus with price targets up to $62, and InvestingPro indicates the stock is undervalued with "GREAT" financial health. The company projects approximately $276 million in total revenue for 2025, showing 23% growth in Q4, and BTIG reiterated a Neutral rating following better-than-anticipated Q3 results.
Vericel stock hits 52-week high at $35.84 despite yearly decline
Vericel stock recently reached a high of $35.84, a notable recovery despite a 38% decline over the past year. Analysts maintain a "strong buy" consensus with price targets up to $62, and InvestingPro data indicates the stock is undervalued with "GREAT" financial health. The company also announced preliminary unaudited 2025 revenues of $276 million, showing strong growth in Q4.
Thrivent Financial for Lutherans Trims Stock Holdings in Vericel Corporation $VCEL
Thrivent Financial for Lutherans significantly reduced its stake in Vericel Corporation (NASDAQ:VCEL) by 36.8% in the third quarter, selling 116,509 shares. Despite this, Vericel reported a stronger-than-expected quarter with $0.10 EPS, beating previous consensus estimates. The stock, currently trading in the mid-$30s, holds a "Moderate Buy" consensus rating from analysts.
Vericel Corp (NASDAQ:VCEL) Presents a Strong Growth and Breakout Setup
Vericel Corp (NASDAQ:VCEL) is highlighted as an attractive investment due to its robust fundamental growth, including significant EPS and sales increases, and strong profitability in the biotechnology sector. Technically, the stock shows a potential breakout setup with a sideways trading pattern near support and minimal overhead resistance. This combination of strong fundamentals and a favorable technical formation suggests a future upward movement for the stock.
Vericel: A GARP Investment with Strong Fundamentals and Clear Catalysts
Vericel Corporation is highlighted as a "Growth At a Reasonable Price" (GARP) investment due to its strong financial position, including a debt-free balance sheet and consistent revenue growth of around 15%. The company, specializing in advanced therapies for sports medicine and severe burn care, shows particular momentum with its MACI therapy. Investors are looking forward to the full-year and Q4 2025 financial results on February 26, 2026, for further insight into its profitability and future guidance.
Vericel: A GARP Investment with Strong Fundamentals and Clear Catalysts
Vericel Corporation is highlighted as a "Growth at a Reasonable Price" (GARP) investment opportunity due to its strong financial position, including a debt-free balance sheet, and consistent revenue growth. The company, which specializes in advanced therapies for sports medicine and severe burn care, has shown an average revenue increase of about 15.01% in recent years. Investors are eagerly awaiting Vericel's Q4 and full-year 2025 financial results on February 26, 2026, to assess its continued growth trajectory and future guidance.
Vericel Corp (NASDAQ:VCEL) Emerges as a Prime GARP Investment Candidate
Vericel Corp (NASDAQ:VCEL) is identified as a strong "Growth at a Reasonable Price" (GARP) investment candidate due to its substantial growth profile, including a 300% EPS increase and projected future growth. Despite seemingly high P/E ratios, its valuation is reasonable when compared to biotech industry peers. The company also exhibits strong profitability and a healthy financial standing with no debt, making it an attractive option for investors combining growth and value strategies.
Cartilage Repair-Cartilage Regeneration Market Covering Prime Factors and Competitive Outlook till 2026 || Vericel Corporation,Smith & Nephew PLC,Osiris Therapeutics Arthrex RTI Surgical
This article forecasts the Cartilage Repair-Cartilage Regeneration Market's growth drivers, competitive landscape, and key players until 2026. It highlights factors such as the rising incidence of orthopedic injuries, technological advancements, and increasing awareness of advanced treatments. The report also details market segmentation by application, treatment modality, and geography, alongside profiling major companies in the sector.
VERICEL CORP (NASDAQ:VCEL) Fits the "Growth at a Reasonable Price" Profile
Vericel Corp (NASDAQ:VCEL) has been identified as a "Growth at a Reasonable Price" investment, demonstrating strong growth potential combined with fair valuation relative to its industry. The company, which specializes in cellular therapies, exhibits solid recent and projected revenue and EPS growth, backed by favorable profitability and financial soundness metrics despite some minor balance sheet considerations. This profile suggests VCEL could offer significant growth opportunities without the high valuation risks often associated with the biotechnology sector.
Vericel (NASDAQ: VCEL) shares preliminary 2025 results, updates outlook
Vericel Corporation has released preliminary, unaudited financial data for the full fiscal year 2025 in connection with its participation in the 44th Annual J.P. Morgan Healthcare Conference. The disclosure includes estimates for revenue, net income, gross margin, adjusted EBITDA margin, and cash and investments as of December 31, 2025. Vericel cautions investors that these figures are preliminary, unaudited, and subject to change, urging against undue reliance until audited financial statements are finalized.
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wall Street analysts are showing bullish sentiment towards several healthcare stocks. Inspire Medical Systems (INSP), Vericel (VCEL), and Nuvation Bio (NUVB) have all received "Buy" or "Strong Buy" ratings with significant upside potential predicted, according to recent reports from firms like Truist Financial and TD Cowen.
Debt-Free Balance Sheet, MACI Momentum, And Burn Care Portfolio Put Vericel On Investors' Radar
Vericel Corp. (VCEL) reported strong preliminary 2025 results, showcasing a debt-free balance sheet with $200 million in cash, significant revenue growth, and expanding utilization of its MACI product. The company achieved profitability for the second consecutive year and is strategically investing in a new MACI manufacturing facility set to open in 2026, positioning itself for continued growth in sports medicine and burn care.
Vericel reports preliminary 2025 revenue of $276 million
Vericel Corporation announced preliminary unaudited financial results for 2025, expecting total revenue of approximately $276 million, a 23% growth in the fourth quarter. The company anticipates a gross margin of 74% and an adjusted EBITDA margin of 26%, along with GAAP net income profitability for the second consecutive year and $200 million in cash with no debt. Vericel expects continued high revenue growth and increased MACI utilization in 2026, supported by sales force expansion and clinical study progress.
Vericel Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Vericel Corporation (NASDAQ:VCEL) announced it will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 p.m. ET. The company, a leader in advanced therapies for sports medicine and severe burn care, will make the presentation available via webcast on its Investor Relations website. Vericel markets products such as MACI®, Epicel®, and holds North American rights to NexoBrid®.
VCEL Crosses Above Key Moving Average Level
Shares of Vericel Corp (VCEL) have moved above their 200-day moving average, trading as high as $38.63 on Tuesday. This indicates a positive technical trend for the stock, with shares currently up approximately 2.7% on the day. The article notes VCEL's 52-week trading range and suggests further stocks that have also crossed this key technical level.
How Investors Are Reacting To Vericel (VCEL) Reaffirmed Guidance And MACI-Focused Growth Narrative
Vericel recently reported higher fiscal Q3 2025 revenue and reaffirmed its full-year guidance, emphasizing continued growth in its MACI product line despite rising operating expenses. Research firms like Truist Securities and Canaccord Genuity have reiterated positive ratings, indicating institutional confidence in Vericel's strategy. The investment narrative hinges on MACI's ability to drive revenue growth while the company manages increased costs related to manufacturing expansion and headcount.
Truist Slashes PT on Vericel Corporation (VCEL) to $45 From $50
Truist analyst Richard Newitter recently reduced the price target for Vericel Corporation (NASDAQ:VCEL) to $45 from $50, while reaffirming a Buy rating. This decision was part of a broader preview for the MedTech sector, following the company's strong fiscal Q3 2025 results which showed increased net revenue. Vericel, a developer of patient-specific cellular therapies like MACI and Epicel, also provided full-year revenue guidance of $272-$276 million and reaffirmed its profitability projections.
Truist Slashes PT on Vericel Corporation (VCEL) to $45 From $50
Truist analyst Richard Newitter has lowered the price target on Vericel Corporation (NASDAQ:VCEL) to $45 from $50, while reaffirming a Buy rating. This adjustment comes despite Vericel reporting strong fiscal Q3 2025 results with increased total net revenue and positive full-year guidance. The article highlights Vericel's product portfolio, including Epicel and MACI, which address severe burn treatments and cartilage repair, respectively.
Vericel (VCEL) Sees Target Price Lowered by Truist Securities
Truist Securities has lowered its target price for Vericel (VCEL) from $50.00 to $45.00 while maintaining a "Buy" rating. This 10% decrease comes after several fluctuations in target prices from various analysts in recent months. Despite the adjustment, the consensus among brokerage firms indicates an "Outperform" status for VCEL, with an average target price implying over 50% upside from its current trading price.
Osterweis Capital Management Inc. Takes $9.71 Million Position in Vericel Corporation $VCEL
Osterweis Capital Management Inc. has acquired a new stake of 228,275 shares, valued at approximately $9.71 million, in Vericel Corporation ($VCEL) during the second quarter. This move makes Osterweis Capital Management the owner of 0.45% of Vericel. The biotechnology company recently surpassed earnings estimates and has received a "Moderate Buy" rating from analysts with an average price target of $58.75.
Vericel Corp (NASDAQ:VCEL) Emerges as a Top GARP Investment Candidate
Vericel Corp (NASDAQ:VCEL) has been identified as a strong "Growth at a Reasonable Price" (GARP) investment candidate due to its robust growth profile, with significant revenue and EPS increases. While its valuation multiples appear high on a straight basis, they are considered acceptable within the high-growth biotechnology sector when balanced against its projected earnings growth and firm profitability. The company also exhibits strong foundational metrics, including high profitability and financial soundness, making it an attractive prospect for GARP-focused investors.
Vericel (VCEL) director Wotton sells $189500 in stock
Vericel Corp (VCEL) director Paul K Wotton sold 5,000 shares of common stock in two transactions on December 2nd and 3rd, 2025, totaling $189,500. These sales, ranging from $37.83 to $37.97 per share, reduced Wotton's direct ownership to 25,602 shares. The sales were reported following Vericel's strong third-quarter 2025 performance, which exceeded earnings expectations.
Insider Sell: Paul Wotton Sells 5,000 Shares of Vericel Corp (VCEL)
Paul Wotton, a Director at Vericel Corp (VCEL), sold 5,000 shares of the company on December 3, 2025, reducing his holdings to 25,602 shares. This transaction is part of a trend of insider selling at Vericel, with 19 insider sells and 0 insider buys over the past year. Vericel Corp, trading at $37.9, is considered modestly undervalued with a price-to-GF-Value ratio of 0.79.
Director’s Big Move: Vericel Stock Sale Shakes Up the Market!
Director Paul Wotton recently sold 5,000 shares of Vericel (VCEL) stock for $189,500, following positive Q3 financial results driven by strong MACI product line revenue. Despite some challenges like potential government shutdown impacts and reimbursement issues, Vericel's strategic initiatives for international expansion and MACI Ankle program position it for continued growth, earning it an "Outperform" rating from TipRanks’ AI Analyst, Spark, though its high P/E ratio suggests potential overvaluation.
There's No Escaping Vericel Corporation's (NASDAQ:VCEL) Muted Revenues Despite A 29% Share Price Rise
Vericel Corporation's shares have seen a 29% surge recently, yet the company's revenue growth remains underwhelming compared to its industry peers. Its low price-to-sales (P/S) ratio of 8x, significantly below the industry average, reflects concerns about its future revenue potential. Analysts forecast a 19% annual growth for Vericel over the next three years, which is substantially lower than the industry's predicted 129% growth, contributing to its subdued P/S ratio.
Vericel’s chief medical officer sells $64,659 in VCEL stock
Vericel's Chief Medical Officer, Jonathan Mark Hopper, sold 1,652 shares of VCEL stock for $64,659 on December 2, 2025, while also exercising options to acquire an equivalent number of shares. This transaction was part of a pre-arranged trading plan, and Hopper now directly owns 66,562 shares. The company recently reported strong Q3 2025 earnings, surpassing revenue and EPS expectations.
New York State Common Retirement Fund Increases Position in Vericel Corporation $VCEL
The New York State Common Retirement Fund has increased its stake in Vericel Corporation by 3.3%, now holding 890,509 shares valued at $37.89 million, representing 1.76% ownership. Vericel (NASDAQ:VCEL) recently reported strong quarterly earnings, beating analyst estimates with $0.10 EPS and revenue up 16.6% year-over-year. Analysts have a "Moderate Buy" consensus rating with an average price target of $58.75.
Vericel Corp Ord earnings beat by $0.11, revenue topped estimates
Vericel Corp Ord (NASDAQ: VCEL) reported strong third-quarter results, beating analyst expectations for both earnings per share (EPS) and revenue. The company posted an EPS of $0.10, significantly outperforming the analyst estimate of -$0.01, and revenue of $67.5 million, topping the consensus estimate. Vericel also provided a positive revenue outlook for FY 2025, anticipating $272.00M-$276.00M.
Vericel (NASDAQ:VCEL) to report Q3 2025; conference call and webcast on Nov. 6
Vericel (NASDAQ:VCEL) will report its third-quarter 2025 financial results on Thursday, November 6, 2025. Management will host a conference call and live webcast at 8:30 a.m. ET to discuss financial results and business highlights and investors can access the webcast and presentation slides via the company's investor relations website. A replay of the webcast will be available until November 6, 2026.
Vericel Corp SEC 10-Q Report
Vericel Corp (VCEL) has released its Form 10-Q report for the third quarter of 2024, showing significant financial growth and operational advancements. The company reported a total revenue of $67.5 million, an increase of 16.6%, and a net income of $5.1 million, reflecting strong revenue growth and cost management. Key drivers include increased demand for MACI, the launch of MACI Arthro, and plans for a new manufacturing facility and future clinical trials.
Vericel Corporation Q3 2025 Financial Results
Vericel Corporation reported record revenue and significant growth for Q3 2025, with total net revenue reaching $67.5 million, up from $57.9 million in Q3 2024. The company achieved a net income of $5.1 million and improved its gross margin to 73.5%. Vericel also highlighted strong performance in its MACI® and burn care product lines, positive operational developments, and maintained a robust financial outlook for the full year 2025.
Vericel Corp (VCEL) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...
Vericel Corp (VCEL) reported record Q3 2025 total revenue of $67.5 million, surpassing guidance with a 25% increase in Macy revenue and achieving a GAAP net income over $5 million. The company generated strong operating cash flow and is preparing for a phase 3 Macy ankle clinical study while managing potential uncertainties in 2026 guidance and variability in burn care revenue. Macy Arthro is contributing to growth by expanding usage in new cases and surgeon targets without cannibalizing existing Macy procedures.
Vericel Corporation (NASDAQ:VCEL) Q3 2025 Earnings Call Transcript
Vericel Corporation reported strong Q3 2025 financial results, exceeding revenue guidance with record total revenue of $67.5 million, largely driven by MACI revenue growth of 25%. The company achieved significant profit growth and cash generation, including a record $22.1 million in operating cash flow. Vericel also provided optimistic guidance for full-year 2025, expecting total revenue between $272 million and $276 million, and detailed plans for MACI's continued expansion, including the MACI Arthro launch, a sales force expansion, and international growth into the U.K.
Vericel Corporation (NASDAQ:VCEL) Surpasses Earnings Estimates with Strong Q3 2025 Results
Vericel Corporation (NASDAQ:VCEL) exceeded analyst expectations for Q3 2025, reporting record revenue of $67.5 million and a profit of $0.10 Non-GAAP EPS against an anticipated loss. This strong performance, driven by growth in its MACI and burn care product lines, led to a pre-market stock increase and the company reaffirming its full-year 2025 guidance. Vericel highlighted its robust financial health with $185 million in cash and no debt, positioning it for continued future growth.
Vericel Corporation Q3 2025 Financial Results
Vericel Corporation announced strong financial results for Q3 2025, reporting record revenue of $67.5 million and a net income of $5.1 million. The company's MACI® product line and burn care segment drove significant growth, supported by strategic initiatives like the MACI Ankle™ program and expanded manufacturing capabilities. Vericel reaffirmed its full-year 2025 revenue and profitability guidance, anticipating continued high growth.
Truist Lowers PT on Vericel Corporation (VCEL) to $41 From $46
Truist has lowered its price target on Vericel Corporation (VCEL) to $41 from $46, while maintaining a "Buy" rating on the shares. This adjustment comes as part of a broader research note previewing Q3 results in MedTech, with Truist anticipating stock volatility despite healthy revenue and earnings. Vericel Corporation specializes in patient-specific cellular therapies, including Epicel for burn treatment and MACI for cartilage repair.
Leerink Partnrs Has Bearish Estimate for Vericel Q4 Earnings - Defense World
Leerink Partners has issued a bearish estimate for Vericel's (NASDAQ:VCEL) Q4 earnings, projecting non-GAAP EPS of ($0.09). This comes amidst recent analyst rating changes and price target adjustments from other firms. Vericel is currently trading down 3.0% and faces scrutiny from hedge funds adjusting their stakes in the company.
Brokerages Set Vericel Corporation (NASDAQ:VCEL) PT at $60.40 - Defense World
Several brokerages have recently adjusted their ratings and price targets for Vericel Corporation (NASDAQ:VCEL). BTIG Research lowered its rating to "neutral," while Canaccord Genuity Group reduced its target price but maintained a "buy" rating. Stephens reissued an "overweight" rating with a $67.00 target price.
Here’s Why Vericel Corp. (VCEL) Traded Down in Q2
Vericel Corporation (NASDAQ:VCEL) saw its shares decline in Q2 2025 despite an overall strong market, according to TimesSquare Capital Management's investor letter. While the company's total revenue increased and gross margin expanded, its burn care results fell below guidance, causing a -5% drop in stock value. As of the end of Q2, 14 hedge funds held positions in Vericel.
Leerink Partners Raises the PT Vericel (VCEL), Maintains a Buy Rating
Leerink Partners raised its price target for Vericel Corporation (VCEL) from $50 to $57, maintaining a Buy rating despite the company narrowly missing Q2 revenue estimates. The analyst believes management's strategic plans and improving MACI Arthro conversion rates will drive growth through 2026, finding the current valuation attractive given stable expense expectations.
Vericel Corporation (VCEL): A Bull Case Theory
This article summarizes a bullish thesis on Vericel Corporation (VCEL), highlighting its transformation into a profitable, debt-free leader in regenerative medicine, specifically sports medicine and severe burn care. The company shows strong growth with MACI and NexoBrid products, rapidly scaling profitability, and compelling valuation metrics, including a price target of $59.
Regenerative Medicine Market Size to Hit USD 169.55 Billion by 2034
The regenerative medicine market is projected to reach USD 169.55 billion by 2034, growing at a CAGR of 16.81% from its 2024 valuation of USD 35.85 billion. This growth is driven by the increasing prevalence of chronic diseases, demand for organ and tissue replacements, advancements in stem cell and gene therapy, and supportive government policies. North America dominated the market in 2024, with the therapeutics segment holding the largest share and dermatology being the leading therapeutic category.
VCEL stock touches 52-week low at $37.42 amid market challenges
Vericel Corporation (NASDAQ: VCEL) stock recently hit a 52-week low of $37.42, reflecting broader challenges in the biotechnology sector despite the company's "GOOD" financial health and strong liquidity. The downturn comes amidst significant revenue growth and a record gross margin in Q4 2024, driven by MACI product performance. Analysts maintain a "Buy" rating, foreseeing future growth from strategic initiatives and new product launches like MACI Arthro.
FDA Approves Arthroscopic Delivery of Vericel’s MACI for Knee Cartilage Defects
The FDA has approved Vericel Corporation’s MACI Arthro for repairing knee cartilage defects, offering a less invasive arthroscopic delivery method. This approval is expected to significantly increase MACI's market penetration and revenue growth, targeting a broader surgeon base and an estimated 20,000 patients annually. While MACI is contraindicated for certain conditions and carries risks, it represents a significant advancement in cartilage repair for full-thickness defects.
Vericel: Pioneering sports medicine & burn care
Vericel (Nasdaq:VCEL) is a biopharma company specializing in sports medicine and severe burn care, offering products like the cartilage repair treatment MACI and burn treatments Epicel and NexoBrid. MACI helps prevent osteoarthritis by repairing cartilage defects with a patient's own cells, while Epicel provides permanent skin replacement and NexoBrid offers an enzymatic solution for burn debridement. The company boasts significant growth and profitability due to its unique position in markets with limited competition and high barriers to entry.
Burlington Celebrates Milestone In New Life Science Project
Burlington, MA, celebrated a significant milestone with a topping-off ceremony for a new 270,000 square-foot life science development at 25/27 Blue Sky Drive. This campus will house a new Genomics Center for the Broad Institute and become the new headquarters for Vericel Corp., bringing approximately 700 jobs to Burlington. This development highlights Burlington's growing role as a hub for life science companies seeking affordable space outside of Boston and Cambridge.
Broad Institute leases room to grow in Burlington
The Broad Institute, a renowned Kendall Square research center, is expanding its operations by leasing 145,705 square feet of lab, research, and office space in Burlington, Massachusetts, joining biopharma company Vericel Corp. The move is part of the Broad Institute Genomics Platform's plan to build an advanced, custom facility to further its work on human disease. This expansion highlights Burlington's growing attractiveness as a life-science hub, spurred by rezoning efforts and significant interest from biotech companies.
Vericel Planning New Cell Therapy Manufacturing Facility
Vericel has entered into a long-term lease agreement for a new 125,000 sq ft cell therapy manufacturing facility and corporate headquarters in Burlington, Mass. This facility will significantly expand the company's manufacturing capacity for its MACI and Epicel products to support long-term growth. Commercial manufacturing is projected to begin in 2025, with the new facility contributing to the existing LEED Gold and Fitwel Level 2 certifications of the campus.
Report: Vericel to supply Epicel-based grafts for baby born without skin
Vericel is providing Epicel-based skin grafts for a baby born in Texas without skin, adapting its burn treatment product for an off-label use. Doctors are working to understand the baby's condition, which was initially misdiagnosed as epidermolysis bullosa. Despite limited data on off-label long-term outcomes, the company notes a 90% survival rate for patients receiving Epicel grafts and does not plan to expand its label beyond serious burns.
